Clinical Trial Update: Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating exenatide's effect on 24h urinary albumin excretion rate in patients with diabetic nephropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Diabetic Nephropathies | Phase 4 | Status: COMPLETED